Author/Authors :
Saia، نويسنده , , Francesco and de Feyter، نويسنده , , Pim and Serruys، نويسنده , , Patrick W. and Lemos، نويسنده , , Pedro A. and Arampatzis، نويسنده , , Chourmouzios A. and Hendrickx، نويسنده , , Guy R. and Delarche، نويسنده , , Nicholas and Goedhart، نويسنده , , Dick and Lesaffre، نويسنده , , Emmanuel and Branzi، نويسنده , , Angelo، نويسنده ,
Abstract :
We assessed the impact of long-term fluvastatin treatment on adverse atherosclerotic cardiac events (cardiac death, myocardial infarction, and revascularization excluding repeat interventions due to restenosis in the first 6 months) in 847 patients (fluvastatin [n = 417] or placebo [n = 430]) with average cholesterol levels treated with stents in the Lescol Intervention Prevention Study (LIPS). During the 4-year follow-up period, fluvastatin significantly decreased total cholesterol and low-density lipoprotein cholesterol levels and decreased the risk of first adverse atherosclerotic cardiac events by 30% compared with placebo (95% confidence interval −49 to −3.4, p = 0.03).
